Crinetics Pharmaceuticals Advised in $40 Million Series A Financing

Innovative therapeutics company focused on specialty endocrine disorders.

November 4, 2015

Crinetics Pharmaceuticals, an innovative therapeutics company focused on specialty endocrine disorders, has announced the completion of a $40 million Series A financing led by 5AM Ventures, Versant Ventures, and Vivo Capital.  The company plans to use the proceeds to advance development of its small molecule somatostatin agonist program to clinical proof-of-concept for the treatment of acromegaly, as well as to move additional programs into development. Latham & Watkins LLP represented Crinetics Pharmaceuticals in the completion of its Series A financing with a corporate team led from the firm’s San Diego office by partner Cheston Larson, with associates Christopher Geissinger and Alaina Ellis. Advice has also been provided on benefits and compensations matters by counsel Holly Bauer in San Diego.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.